Objective: The goal of this 10-year naturalistic study was to examine, in clozapine-treated pa tients, the change in cardiovascular risk factors following clozapine initiation and the mortality estimates from cardiovascular disease.
.2.. A. risk of mortality have long beth associated with schizophrenia. Ciozapine remains the treatment of choice for treatment-resistant schizophrenia and associ ated disorders because of its greater efficacy and relative lack of extrapyramidal side effects compared to conven tional antipsychotic medications.t Growing concerns with clozapine treatment are related to side effects such as weight gain, hyperglycemia, hyperlipidemia, and hyper terjsion. Fontaine et al. 4 estimated the expected i ct of antipsychotic_hdtc.d`.veight gain on moraflt: ras and incidence of in17:'d glucose tolerance ICTI and hypertension using raw data from 5209 reswndentJrom the Framinghatn Heart Study. Results indicated that th estimated deleterious effects of weight gain were greater for people with higher body mass index BMI at base line, people with greater degrees of weight gain, men, and older persons. Additionally, the effect of weight gain on JOT and hypertension was deleterious regardless of base line EM!. PEychotropic medications,`in.. general, mall produce .significini weight gain. Incur 5-ye?r naturalistic study, we found that wcightgain with.ciozapine,did not plateau until The fourth year. 3 Umbricht and colleagues6 reported that almost half of 82 patients gained 20% or more of their Ciozapine, Diabetes Mellitus, Hyperlipidemia, and Cardiovascular Risks and Mortality: Results of a 10-Year Naturalistic Study
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body weight during clozapine treatment for up to 90 months. A 7% or greater increase in weight is considered the standard indicator for extreme weight gain in clinical trials. An increase in body weight of 7% or greater is gen erally regarded as a high-risk event, A large number of published case reports have also linked treatment-emergent type 2 diabetes mellitus to the use of atypical agents, with clozapine and olanzapine most frequently cited.7 Clozapine treatment has been as sociated with insulin resistance independent of adiposity in schizophrenia patients.8 When insulin resistance oc curs, the body attempts to overcome this resistance by secreting more insulin, resulting in hyperinsulinernia. Abnormalities associated with insulin resistance include glucose intolerance, hypertension, a prothrombic state, and dyslipidemia. These metabolic abnormalities have been associated with metabolic syndrome and cardiovas cular disease individually and together have been found to greatly increase cardiovascular mortality. 9 Several risk factors for coronary disease, including cigarette smoking, obesity, hypertension, elevated serum lipids, and diabetes mellitus, have been identified in the general population. Because these factors are supra additive, the risk for cardiac disease is increased almost 12-fold in individuals who have all 5 risk factors com pared to those who have none0 The purpose of the present study was to examine in clozapine-treated sub jects the change in risk factors for cardiovascular disease, as well as the rate and estimates of diabetes mellitus and cardiovascular disease-related mortality, after clozapine initiation, over a 10-year period.
METHOD
Following institutional review board approval, 96 pa tients with schizophrenia or schizoaffective disorder DSM-IV criteria who had been treated with clozapine for up to 10 years from January 1992 to December 2003 were e.'camined for known diabetes and cardiovascular risk factors.'0 Cardiovascular risk was tabulated using the fllcving criteria: race African American, Hispanicf Laino Amrica.
American I poi:: EM! 27 kg'nt = 1 point liypMension systolic blood pressure 140mm Hg or diastolic blood pressure 90 rum hg = I point; diabetes mellitus = I point; cigarette smoking point; history of left ventricular hypertrophy, myocardial infarction, or cerebrovascular accident = I point; total cholesterol level 200 mg/OL or serum triglyceride level 150 mgldL = 1 point; and male gender = I point. Car diovascular risk factors were tabulated at 1-year intervals over a 10-year period.
Autopsy reports and all medical records were reviewed by a research psychiatrist D.C.H. to determine the cause of death. When cardiovascular disease was identified, all records were carefully reviewed to determine if any evi dence of clozapine-associated myocarditis or cardiomy opathy was present prior to the death such as persistent tachycardia, left ventricular hypertrophy, a prolonged cor recteti QT interval, eosinophilia, dyspnea on exertion, -exercise intolerance, or edema"2
Statistical Analysis
This study examined time to development of diabetes meflitus and death from cardiovascular disease associated with clozapine treatment at 12-month intervals over a 10-year period. Baseline and follow-up descriptive statis tics were tabulated. Weight, serum cholesterol level, and serum triglyceride level were treated as continuous vari ables and analyzed by means of longitudinal methods. The Cox proportional hazards regressions were used to test the association between the covariates age, ethnicity, BMI, total cholesterol level, serum triglyceride level, sys tolic and diastolic blood pressure, smoking, and diabetes mellitus and death from cardiovascular disease and the development of diabetes mellitus. Age, race, and gender were analyzed as baseline covariates, and BMJ, total cho lesterol level, clozapine total daily dose, serum triglycer ide level, and weight were analyzed as time-dependent covariates. Each covariate was analyzed separately.
Time was used as a stratum and ties were handled with the discrete option in the SAS PHREG procedure SAS Institute Inc., Cary, N.C.. This replaces the proportional hazards model with the discrete logistic model so that odds ratios rather than hazard ratios are computed. The Kaplan-Meier estimate of time to development of diabe tes mellitus and cardiovascular death were computed. Changes from baseline in weight, BMI, total cholesterol level, and serum triglyceride level were analyzed by using a mixed-effects model. This model has fixed linear term for time and random intercept and linear term for time for each patient. The fixed effects estimate the mean trajec tory of the change from baseline, and the random effects allow a separate trajectory for each patient. All p values are 2-tailed, and a p value c .05 was considered evidence for stalistical significance.
:CSUL' S Baseline demographic and laboratory measures are presented in Table 1 . Sixty-nine subjects 72% were men and 27 28% were women. The mean ± SD age at cloza pine initiation was 36.5 ± 7.9 years; 6 subjects 6% were African Americans,4 4% were Hispanic Americans, and 1 1% was an Asian American. The mean length of treat ment with clozapine was 90 ± 37 months.
The random slopes model indicated that BMI in creased significantly over time; the linear coefficient was 0.033 kg/m1/month, SE = 0.005, = 6.48, df= 94, p c .0001. Weight also increased significantly over time linear coefficient of 0.21 lb/month, SE = 0.03, t = 6.29, df= 92, p <.0001. The mean increase in weight was ap proximately 30 lb. Unlike in most previous reports of weight stability after an early weight gain,hit4 many pa tients experienced a second prolonged period of weight gain following a leveling off after se'eral months or years. Fifteen of these patients had a significant change in lifestyle such as moving from a residential program where diet was closely monitored to; an independent apartment. There was a significant incrse in serum tri glyceride levels linear coefficient of 045 mg/dL/nionth, SE = 0,238, t = 2.08, df= 89, p = .04 but not total cho lesterol levels linear coefficient of -0.1, SE=0567, r=-1.55, df=90, p =13. There was a siniflcant increase in nwnber of cardio vascular risk factors mixed-effects model, t = 9.3, df = 95, p c .000i over time. Fgurc I sio': the cha;5e in cardiovascular risk factors over the 10-year period. Table  2 provides demographic and background information for patients who experienced a cardiovascular-related event.
Five confirmed cardiovascular disease-related deaths oc curred during the 10-year period. Of thee 5 patients v1io died, 2 were less than 30 years of age, B were smokers, and 2 received treatment for diabetes niellitus following clozapine initiation. In addition, 3 patients experienced nonfatal myocardial infarctions and 1 suffered a cerebro vascular accident. Two additional patients experienced cardiovascular disease-related deaths but were excluded from the overall sample since baseline cardiovascular risk assessments, prior to clozapine initiation, were not avail- Thirty-ih;cc paI:r.ts 34% deveopd daices over the 10-year period. However, the Kaplan-hticr estimate for new-onset diabetes mellitus was approximately 43% if each patient had taken the drug for the full 10-year period Figure 3 . Results from the Cox proportional odds model indicated that African American OR = 11.5, 95% CI = 3.59 to 36.88 and Hispanic American OR = 4.3, 95% CI = 1.19 to 15.55 patients showed elevated risks of developing diabetes melhitus compared to white patients. BMI OR= 1.11, 95% CI= 1.04 to 1.17, total cholesterol level OR = 1.006, 95% Cl = 1.00 to 1.01, and serum triglyceride level OR = 1.002, 95% Cl = 1.000 to 1.003 significantly increased the odds ratio for the development of diabetes mellitus. However, age Of note, 8 patients developed diabetes mellitus that: subsequently resolved following interventions including nutrition and exercise programs N = 3, lowering of the clozapine dose following the initiation of another antipsy chotic agent N = 3, and discontinuation of clozapine N = 2. Additionally, 10 subjects were identified as at risk secondary to impaired fasting glucose level glucose > 110, <126 mg/dL or elevated random glucose level >160 mg/dL on several occasions. Interventions were undertaken in these patients to prevent the development of diabetes, including exercise and nutrition programs and the use of appetite-suppressing agents. Overall, 30 patients participated in weight intervention programs or sttdies that may have reduced their risk for diabetes me] titus. Further, all patients repeatedly received nutrition and exercise counseling between years 5 and 10. Al though 6-4% of patients were sniolcers at baseline. 10% were able to Quit following successful participation in a smoking cessation prcrami PISCUSSION Clozapine appears to increase the rates of several medical disorders, including obesity, hyperlipidernia, hy pertension, and diabetes mellitus. Long-term clozapine treatment resulted in an increase in number of risk factors for diabetes and cardiovascular disease. As expecied, the increase in risk factors for diabetes and cardiovascular disease escalated over time. The cardiovascular deaths are most concerning, as 2 occurred in patients below the age of 30 years. Additionally, nonfatal cardiovascular events also occurred in this patient cohort. Risk factors such as ethnicity and EMI ma9 increase the risks for The rates in our clozapine cohort greatly exceed both the United States and Massachusetts cardio vascular disease-related death rates. This finding also suggests that the gains in life expectancy made by clozapine's reduction in suicide rates in schizophrenia pa tients may be lost sccondary to cardiovascular diseaserelated deaths. Dyslipidemia represents one of the most important risk factors for cardiovascular morbidity and mortality.20 High total cholesterol and low-density lipoprotein cholesterol levels are strong independent risk factors for coronary heart disease.21 Hypertriglyceridemia is also an indepen dent risk factor for coronary artety disease and insulin re sistance.2 Among lipid parameters in our study, only se rum triglyceride level was shown to increase significantly overtime.
Weight gain and obesity contribute markedly to the risk for a number of diseases, including diabetes mellitus, cor onary artery disease, hypertension, gallbladder disease, os teoarthritis, and colon, breast, and uterine cancers.24 Ab dominal visceral adiposity, in particular, increases the risk for diabetes mellitus and cardiovascular disease. The risk for diabetes has been reported to be approximately 2-fold in mildly obese, 5-fold in moderately obese, and 10-fold in severely obese persons! Weight gain leading to obesity is a significant problem with clozapine and is often difficult to reverse.2621 Finally, some patients experienced a second period of weight gain that occurred when they improved enough to leave structured environments, such as residential settings, to move to independent apartments. While clozapine may lead to an increase in functioning re sulting in more independent living, this may also place pa tients at higher risk for weight gain, obesity, and metabolic deterioration.
Clozapine also appears to increase the rate of hyperten sion in patients with chronic schizophrenia.28 llypeiien sion mark:dly increases the t-irk for myocardial infarction. congestive heart disease, stroke, and renal failure. It is in creaingly evident that high blood pressure is a relatively late developing component of a cluster of pathologic changes that may include loss of vascular elasticity, obe sity, abnormal lipid metabolism, insulin resistance, and re nal disease and that these changes reflect comlex genetic and environmental factors.
African Americans and Hispanic Americans in this study, as well as in the general population,29 appear to be at greater risk for developing diabetes mellitus, and in this study, for death from cardiovascular disease following clozapine treatment. Hypervigilance in these populations should be undertaken with screening, assessment and Increased monitoring, such as for weight and blood pres sure at every visit, along with an increase in the monitor ing of glucose every 6 months and lipids once a year should be considered.
There are several limitations to this current study. First, it is possible that other unknown factors affected the rates of diabetes and cardiovascular disease-related deaths. While we identified African American and Hispanic American patients as having the greatest risk, it is possible that other risk factors or predispositions, including family history, contributed to the outcomes. Finally, although medical records, autopsy reports, and emergency depart ment records were reviewed, it is possible that undetected cardiomyopathy or myocarditis contributed to the cardio vascular deaths. However, our results support the fmdings of Fontaine eta!.,4 which suggested that the lives saved via clozapine's reduction in suicide may essentially be offset by the deaths due to weight gain. Additionally, many pa tients participated in interventions to reduce risk factors for diabetes and cardiovascular disease, and these efforts may have reduced the overall incidence of new-onset dia betes rnellitus or cardiovascular death in this patient co hort. It is possible that, without these interventions, many more patients would have developed diabetes mellitus and experienced cardiovascular events.
Long-tenn treatment with clozapine may significantly increase the risk of death from cardiovascular disease, with an estimate of up to 9% of clozapine-treated patients dying from cardiovascular disease over a 10-year period.
Cardiovascular symptoms must be taken seriously in this population. Monitoring and assessing risks for diabetes and cardiovascular disease should be undertaken routinely, and interventions to reverse or prevent such occunences shoujd be instituted. While reasonable monitoring guide lines have recently been published by the American Diabe tes Association,30 high-risk populations such as African Arnerican and Hispanic American patients must be moni tored even more closely.
